TriangleNCT02039947 · OUTCOME
Extracranial Response Rate (ER) for Each Cohort
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Number of participants
- Interval / dispersion
- Not reported
- Time frame
- Approximately 2 years
What was measured
Extracranial Response Rate was defined as the percentage of participants with Complete response (CR) or Partial response (PR) at anytime. This is based on investigator-assessed response. No hypothesis testing completed for cohort A,B,C and D
Analysis population: All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population
Groups in this outcome
Cohort A
Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
Cohort B
Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
Cohort C
Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
Cohort D
Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
| Group | Source count |
|---|---|
| Cohort A | 76 |
| Cohort B | 16 |
| Cohort C | 16 |
| Cohort D | 17 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A | 42 | Not reported | Not reported | Not reported | Not reported |
| Cohort B | 7 | Not reported | Not reported | Not reported | Not reported |
| Cohort C | 12 | Not reported | Not reported | Not reported | Not reported |
| Cohort D | 7 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 42
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 12
- group Id
- OG003
- value
- 7
- denoms
- counts
- group Id
- OG000
- value
- 76
- group Id
- OG001
- value
- 16
- group Id
- OG002
- value
- 16
- group Id
- OG003
- value
- 17
- units
- Participants
- description
- Extracranial Response Rate was defined as the percentage of participants with Complete response (CR) or Partial response (PR) at anytime. This is based on investigator-assessed response. No hypothesis testing completed for cohort A,B,C and D
- groups
- description
- Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
- id
- OG000
- title
- Cohort A
- description
- Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- id
- OG001
- title
- Cohort B
- description
- Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- id
- OG002
- title
- Cohort C
- description
- Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- id
- OG003
- title
- Cohort D
- param Type
- NUMBER
- population Description
- All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population
- reporting Status
- POSTED
- time Frame
- Approximately 2 years
- title
- Extracranial Response Rate (ER) for Each Cohort
- type
- SECONDARY
- unit Of Measure
- Number of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice